Jafron Biomedical Co (SZSE:300529) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Additional Paid-In Capital?

Jafron Biomedical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥666 Mil) but then stayed the same from Dec. 2023 (¥666 Mil) to Mar. 2024 (¥0 Mil).

Jafron Biomedical Co's annual additional paid-in capital increased from Dec. 2021 (¥589 Mil) to Dec. 2022 (¥669 Mil) but then declined from Dec. 2022 (¥669 Mil) to Dec. 2023 (¥666 Mil).

Jafron Biomedical Co Additional Paid-In Capital Historical Data

The historical data trend for Jafron Biomedical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Additional Paid-In Capital Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

579.88

308.92

589.50

668.91

665.92

Jafron Biomedical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	671.49	-	665.92	-

Jafron Biomedical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Jafron Biomedical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines